Potential virostatics. Part 3: NMR Studies in quinoxalines and s-triazolo (4,3-a) quinoxalines
Schleinitz, K.D.; Westphal, G.; Köppel, H.; Wasicki, H.
Die Pharmazie 35(2): 84-86
1980
ISSN/ISBN: 0031-7144 PMID: 7384188 Document Number: 167957
Examples of different tautomeric forms were detected in a series of modified quinoxalines by means of nmr spectrometry. Apart from tautomeric equilibria, certain specially favoured conformers may play a part in biological systems, as illustrated by an example.
Document emailed within 1 workday
Related Documents
Habib, N.S.; el-Hawash, S.A. 1997: Synthesis and antimicrobial testing of thiazolinyl-, thiazolidinonyl-quinoxalines and 1,2,4-triazolo[4,3-a]quinoxalines Die Pharmazie 52(8): 594-598Abbas, H.-A.S.; Al-Marhabi, A.R.M.; Ammar, Y.A. 2017: Design, Synthesis and Biological Evaluation of 2,3-Disubstituted and Fused Quinoxalines as Potential Anticancer and Antimicrobial Agents Acta Poloniae Pharmaceutica 74(2): 445-458
Loriga, M.; Moro, P.; Sanna, P.; Paglietti, G.; Zanetti, S. 1997: Quinoxaline chemistry. Part 8. 2-[Anilino]-3-[carboxy]-6(7)-substituted quinoxalines as non classical antifolate agents. Synthesis and evaluation of in vitro anticancer, anti-HIV and antifungal activity Farmaco 52(8-9): 531-537
Kleckner, N.W.; Dingledine, R. 1989: Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on N-methyl-D-aspartate receptors Molecular Pharmacology 36(3): 430-436
Varano, F.; Catarzi, D.; Colotta, V.; Cecchi, L.; Filacchioni, G.; Galli, A.; Costagli, C. 1997: Tricyclic heteroaromatic systems. 3-substituted 1,2,3,5,6,7-hexahydro-2,5,6-trioxopyrazino[1,2,3-de]-quinoxalines as novel antagonists at the glycine-NMDA site Farmaco 52(3): 179-182
Holla, B.S.; Shivananda, M.K.; Akberali, P.M.; Baliga, S.; Safeer, S. 1996: Studies on arylfuran derivatives-Part VI. Synthesis, characterization and antibacterial activities of some 6-(5-aryl-2-furyl)-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazoles and 6-(5-nitro-2-furyl)-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles Farmaco 51(12): 785-792
Kosáry, J.; Kasztreiner, E.; Lázár, A.; Sóti, M. 1983: Preparation of new [1,2,4]triazolo[4,3-b]pyridazines. Part 12: Studies in the field of pyridazine compounds Die Pharmazie 38(6): 369-371
Baraldi, P.G.; Cacciari, B.; Spalluto, G.; Pineda de las Infants, M.J.; Zocchi, C.; Ferrara, S.; Dionisotti, S.; FerraDDionisotti, S. 1996: 1,2,3-Triazolo[5,4-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: a new class of A2A adenosine receptor antagonists Farmaco 51(4): 297-300
Rinaldi, M.; Pecorari, P.; Costantino, L.; Provvisionato, A.; Malagoli, M.; Cermelli, C. 1992: Synthesis and biological activity of new heterocyclic structures: [1,3]thiazino[2,3-i]purine, thiazolo[3,2-c] [1,2,3]triazolo[4,5-e]pyrimidine and [1,2,3]triazolo [4', 5': 4,5] pyrimido[6,1-b][1,3]thiazine Farmaco 47(10): 1315-1322
Ali, K.A.; Ragab, E.A.; Farghaly, T.A.; Abdalla, M.M. 2011: Synthesis of new functionalized 3-substituted [1,2,4]triazolo [4,3-a]pyrimidine derivatives: potential antihypertensive agents Acta Poloniae Pharmaceutica 68(2): 237-247
Iyer, R.N.; Rao, K.V.B. 1978: Studies in potential antifertility agents: part 20: Synthesis of tetraphenylethane basis ethers & 1, 2-Bis (4'-hydroxyphenyl)-1,2-diphenylethylene Indian Journal of Chemistry. Sect. B 16(7): 601-604
Joshi, K.C.; Pathak, V.N.; Jain, S.K. 1980: Studies of potential organo-fluorine antibacterial agents. Part 5: Synthesis and antibacterial activity of some new fluorine-containing indole-2,3-dione derivatives Die Pharmazie 35(11): 677-679
Ambrogi, V.; Grandolini, G.; Perioli, L.; Giusti, L.; Lucacchini, A.; Martini, C. 1993: Studies on annelated 1,4-benzothiazines and 1,5-benzothiazepines. VII. Synthesis and inhibition of benzodiazepine receptor binding of some 4,5-dihydro-tetrazolo[5,1-d]-1,5-benzothiazepines and 5-phenyl-s-triazolo[3,4-d]-1,5-benzothiazepines Farmaco 48(5): 665-676
Vandendriessche, G.; Van Hecke, J.; Van Herck, G. 1982: The anterior tibial compartmental syndrome. Part 1: Case studies, pathophysiology, etiology and symptoms. Part 2: Diagnosis and treatment: the role of the E.M.G. examination Electromyography and Clinical Neurophysiology 22(6): 433-444
Morozumi, K. 1982: Studies on cortical tissue plasminogen activator in renal disease. Part I: Studies in the glomerulonephritis Nihon Jinzo Gakkai Shi 24(2): 153-166
Dzielska-Olczak, M.łg. 2011: Cyclooxygenases inhibitors and other compounds with antiinflammatory potential in osteoarthrosis--part Ii Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 30(175): 82-86
Evans, D.C.; Baillie, T.A. 2005: Minimizing the potential for metabolic activation as an integral part of drug design Current Opinion in Drug Discovery and Development 8(1): 44-50
Eastland, G.W.; Yang, G.; Thompson, T. 1983: Studies of rhenium carboxylates as antitumor agents. Part II. Antitumor studies of bis (mu-propionato) diaquotetrabromodirhenium (III) in tumor-bearing mice Methods and Findings in Experimental and Clinical Pharmacology 5(7): 435-438
Turner, J.F.; Mason, T.; Anderson, D.; Gulati, A.; Sbarbaro, J.A. 1995: Physicians' ethical responsibilities under co-pay insurance: should potential fiscal liability become part of informed consent? Journal of Clinical Ethics 6(1): 68-72
Almerico, A.M.; Diana, P.; Barraja, P.; Dattolo, G.; Mingoia, F.; Putzolu, M.; Perra, G.; Milia, C.; Musiu, C.; Marongiu, M.E. 1997: Glycosidopyrroles. Part 2. Acyclic derivatives: 1-(1,3-dihydroxy-2-propoxy)methylpyrroles as potential antiviral agents Farmaco 52(11): 667-672